Lu joined Sequoia Capital China Fund in 2005, and she has 13 years of experience in healthcare investment under her belt. Before Sequoia, she took roles in medical equipment and disposables devices marketing and hospital project cooperation, and has accumulated rich industry resources and experience. Currently she represents Sequoia as board of director of more than a dozen companies. She was directly in charge of investments in many early and mid-term stage companies such as Jafron Bio (300529), Snibe Diagnostic (passed review of Issuance Appraisal Committee), ARMO (Nasdaq ARMO), Winner Medical, Shanghai Iray, Shenzhen XtalPi, Peking University Rehabilitation Hospital, etc. They are all leading companies in their respective medical sub-sectors, among which Jafron Bio and Snibe Diagnostic yield ultra-high return
Lu graduated from Tongji Medical College in 1996 with a bachelor's degree in clinical medicine. She received MBA from the Chinese University of Hong Kong in 2004, and EMBA from the Cheung Kong Graduate School of Business in 2015 .
Industry recognition: VB100 Best Investor of the year in 2017. Forbes 2018 TOP25 female venture capitalist in China. FMBA instructor at Cheung Kong Graduate School of Business and mentor of multiple healthcare incubators and start-up camps